Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion

SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laurel Goldin, Ty Elders, Leslie Werhane, Kimberly Korwek, Russell Poland, Jeffrey Guy
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	COVID-19 Sars-Co-V-2 monoclonal antibody Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/05b2db2ae16a4bb2be783a8b09ce7830
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05b2db2ae16a4bb2be783a8b09ce7830
record_format	dspace
spelling	oai:doaj.org-article:05b2db2ae16a4bb2be783a8b09ce78302021-11-30T04:14:07ZReactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion1201-971210.1016/j.ijid.2021.09.007https://doaj.org/article/05b2db2ae16a4bb2be783a8b09ce78302021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S120197122100713Xhttps://doaj.org/toc/1201-9712SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis presents findings from over 6,500 outpatient administrations of mAb at facilities affiliated with a large healthcare organization in the United States. Within 48 hours of mAb infusion, 15.6% (1,043) of patients received a drug that was indicative of a possible reaction to the infusion; the majority of these were mild (e.g., acetaminophen). Approximately 5.2% of patients who received mAb (n=347) had a post-infusion emergency department visit or admission for COVID-19 disease progression. The results of this analysis indicate that patients who receive mAb have a low likelihood of both an immediate negative reaction to the treatment as well as future inpatient admission related to COVID-19 disease progression.Laurel GoldinTy EldersLeslie WerhaneKimberly KorwekRussell PolandJeffrey GuyElsevierarticleCOVID-19Sars-Co-V-2monoclonal antibodyInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 112, Iss , Pp 73-75 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 Sars-Co-V-2 monoclonal antibody Infectious and parasitic diseases RC109-216
spellingShingle	COVID-19 Sars-Co-V-2 monoclonal antibody Infectious and parasitic diseases RC109-216 Laurel Goldin Ty Elders Leslie Werhane Kimberly Korwek Russell Poland Jeffrey Guy Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
description	SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis presents findings from over 6,500 outpatient administrations of mAb at facilities affiliated with a large healthcare organization in the United States. Within 48 hours of mAb infusion, 15.6% (1,043) of patients received a drug that was indicative of a possible reaction to the infusion; the majority of these were mild (e.g., acetaminophen). Approximately 5.2% of patients who received mAb (n=347) had a post-infusion emergency department visit or admission for COVID-19 disease progression. The results of this analysis indicate that patients who receive mAb have a low likelihood of both an immediate negative reaction to the treatment as well as future inpatient admission related to COVID-19 disease progression.
format	article
author	Laurel Goldin Ty Elders Leslie Werhane Kimberly Korwek Russell Poland Jeffrey Guy
author_facet	Laurel Goldin Ty Elders Leslie Werhane Kimberly Korwek Russell Poland Jeffrey Guy
author_sort	Laurel Goldin
title	Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
title_short	Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
title_full	Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
title_fullStr	Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
title_full_unstemmed	Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
title_sort	reactions and covid-19 disease progression following sars-cov-2 monoclonal antibody infusion
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/05b2db2ae16a4bb2be783a8b09ce7830
work_keys_str_mv	AT laurelgoldin reactionsandcovid19diseaseprogressionfollowingsarscov2monoclonalantibodyinfusion AT tyelders reactionsandcovid19diseaseprogressionfollowingsarscov2monoclonalantibodyinfusion AT lesliewerhane reactionsandcovid19diseaseprogressionfollowingsarscov2monoclonalantibodyinfusion AT kimberlykorwek reactionsandcovid19diseaseprogressionfollowingsarscov2monoclonalantibodyinfusion AT russellpoland reactionsandcovid19diseaseprogressionfollowingsarscov2monoclonalantibodyinfusion AT jeffreyguy reactionsandcovid19diseaseprogressionfollowingsarscov2monoclonalantibodyinfusion
_version_	1718406783956942848

Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion

Ejemplares similares